Skip to main content
Adocia logo

Adocia — Investor Relations & Filings

Ticker · ADOC ISIN · FR0011184241 LEI · 969500ZL79KYH9PTYP78 PA Real estate activities
Open in API
Filings indexed 826 across all filing types
Latest filing 2017-06-07 Regulatory Filings
Country FR France
Listing PA ADOC

About Adocia

https://www.adocia.com

Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'PRESS RELEASE' and announces the initiation of a Phase 1b clinical study for a drug candidate (BioChaperone® Combo). It details the study design, endpoints, expected results timeline (Q4 2017), and includes standard sections like 'About ADOCIA' and contact information for press/investors. This format is characteristic of an initial announcement of significant corporate or clinical development news, which aligns best with the 'Earnings Release' (ER) category if it were financial results, but since it is clinical trial initiation, it is a general corporate update. Given the options, this is a specific corporate announcement that is not a formal regulatory filing (like 10-K), a management change (MANG), or a dividend notice (DIV). It is a press release detailing operational progress. While 'RNS' (Regulatory Filings/General Announcement) is a possibility, 'ER' (Earnings Release) often serves as the closest proxy for major periodic operational updates when a specific 'Clinical Trial Update' code is unavailable, but in this context, it is a general corporate announcement. Since it is a press release announcing operational progress (clinical trial initiation) rather than financial results, and it doesn't fit the other specific categories, the most appropriate general category for a non-financial, non-governance press release is often 'RNS' (Regulatory Filings/General Announcement) as a fallback for significant news not covered elsewhere, or potentially 'LTR' if it were legal, but it is not. Given the structure and content (a standard press release announcing a key operational milestone), 'RNS' is the best fit as a general regulatory/corporate announcement fallback.
2017-06-07 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces positive primary results from a Phase 1b clinical study regarding the drug BioChaperone® Combo. It details statistical findings, comparisons to other treatments (Humalog Mix25TM, Lantus/Humalog injections), and includes quotes from management and a key opinion leader. This content structure—announcing key results of a study or period—is characteristic of an Earnings Release (ER) or a general announcement. Since it is specifically announcing clinical trial results rather than general quarterly financial performance (which would lean towards ER or IR), and it is a formal announcement document, it fits best under the category for initial financial/operational result announcements. Given the options, 'Earnings Release' (ER) is the closest fit for a press release announcing significant operational/clinical milestones that impact future earnings potential, although 'Regulatory Filing' (RNS) could also apply if this were a mandatory disclosure. However, the focus on key positive results makes ER the most appropriate classification for this type of corporate news release. FY 2017
2017-06-06 French
Communicated under the obligation to provide permanent information / Other communications
Earnings Release Classification · 1% confidence The document is explicitly titled '# PRESS RELEASE' and announces 'Positive Topline Results' from a clinical study. It details key findings (statistical significance, reductions in blood glucose excursion, hypoglycemic events) and includes quotes from management and clinical experts. This format—a brief announcement of key periodic results, often accompanied by forward-looking statements and contact information—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical milestones. Since the content is focused on announcing the *results* of a clinical trial (a key operational event), and not a full financial report (10-K or IR), the most appropriate classification is Earnings Release (ER), as these releases often cover major clinical trial readouts in the biotech/pharma sector, even if they aren't strictly quarterly financial earnings. FY 2017
2017-06-06 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces the initiation of a clinical study comparing Adocia's BioChaperone® Lispro to existing insulins (Fiasp® and Novolog®). It details the study design, objectives, and expected results timeline. This type of announcement, detailing operational progress, clinical trial updates, and strategic developments, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is a press release announcing operational news rather than a formal regulatory filing like a 10-K or a specific financial report like an IR, and it focuses on key operational milestones (launching a Phase 2 study), the most appropriate classification among the provided options is Earnings Release (ER), as these often contain operational highlights alongside financial context, or Regulatory Filing (RNS) if it were purely informational. Given the content is a major operational announcement intended for the market, ER is a strong fit, although it lacks explicit quarterly results. However, if we strictly follow the definitions, it is an announcement of corporate activity. Since it is a press release announcing a clinical trial update, it is a form of corporate communication. It is not a full report (10-K, IR), a management discussion (MDA), or a presentation (IP). It is a general announcement. In many databases, such press releases fall under ER if they are timely market-moving news, or RNS if they are general regulatory disclosures. Given the focus on clinical progress and expected results, it functions similarly to an update that might accompany or precede an ER. Since it is a press release announcing significant corporate activity (clinical trial launch), and it doesn't fit the other specific categories well (it's not a DIV, CAP, or MANG), it leans towards a general announcement. If we consider the context of financial reporting, ER often includes such operational news. However, if we treat it as a general, non-financial-specific regulatory disclosure, RNS is the fallback. Given the nature of the announcement (clinical trial launch and expected results), it is a significant corporate event disclosure. I will classify it as an Earnings Release (ER) as these often serve as the primary vehicle for disseminating key operational updates to the market, even if explicit P&L figures are absent, or RNS as a general regulatory filing. Given the structure and content (press release format, clinical trial update), RNS (Regulatory Filings - general regulatory announcements and fallback) is the safest classification for a non-standard report announcement, though ER is plausible if this was released around an earnings period. I will select RNS as the best fit for a general press release detailing clinical progress that doesn't match a specific financial report type.
2017-06-01 French
Communicated under the obligation to provide permanent information / Other communications
Earnings Release Classification · 1% confidence The document is explicitly titled '# PRESS RELEASE' and contains typical elements of a press release: a headline announcing a clinical study initiation, bullet points summarizing key facts, a date/time stamp (June 1st, 2017 – 6 pm CET), quotes from management/experts, and a standard 'About ADOCIA' section followed by contact information and a disclaimer. This format strongly indicates an initial public announcement of a significant corporate event (a clinical trial initiation), which aligns best with an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it is a formal announcement, it fits the pattern of an ER, which often covers operational milestones like trial starts, even if it's not strictly quarterly earnings figures. Given the options, ER is the most appropriate classification for a press release detailing operational/clinical progress. FY 2017
2017-06-01 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces the initiation of a Phase 1 clinical study for a product called BioChaperone® Glucagon. It details the study objectives (safety, tolerance, PK/PD profiles), the comparator drug, the study design (randomized, double-blind, cross-over), and provides an expected results timeline (Q4 2017). This content is characteristic of an announcement regarding ongoing research and development activities, often released to the public and investors before a formal regulatory filing like a 10-K or IR. Since it is a press release announcing clinical trial progress and not a formal financial report (10-K, IR) or a transcript (CT), it best fits the category for general corporate announcements or investor updates. Given the options, it is a specific announcement about R&D progress, which is often categorized under Investor Presentation (IP) if it were a deck, or sometimes falls under Regulatory Filings (RNS) if it's a general announcement. However, press releases detailing clinical trial initiation and progress are frequently classified as Investor Presentations (IP) or sometimes Earnings Releases (ER) if tied to a reporting period, but this is purely R&D news. Since it is a formal announcement of a significant corporate/R&D event, and not a formal financial report, the closest fit among the specific options that cover non-financial operational updates is often the general announcement category (RNS) or Investor Presentation (IP) if it were structured as such. Given the nature of the announcement (clinical trial initiation, results expected), it is a key piece of information for investors. It is not a formal financial report, nor a management change, nor a dividend notice. It is most closely aligned with an Investor Presentation (IP) in terms of content focus (strategy/pipeline update), although it is formatted as a press release. Since it is a press release announcing R&D progress, and not a formal financial report, RNS (Regulatory Filings/General Announcement) is a safe fallback, but IP covers detailed pipeline updates well. Given the detailed nature of the clinical trial description, IP is a strong candidate, but RNS covers general press releases about corporate events that don't fit elsewhere. I will classify this as a general announcement/press release, which maps best to RNS, as it is not a formal presentation deck (IP) or an earnings release (ER).
2017-06-01 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.